Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

Past Forum: 2017

Summary

Cardiovascular and cardiometabolic care are among the core drivers of the current healthcare revolution. With 24 million heart disease-related deaths forecasted for 2030, current legacy delivery systems are undergoing disruption by a convergence of new therapies, new technologies, digital integration and the engagement of completely new industries to move patients to improved health and sustained well-being.

At more than $200 billion annually, cardiovascular remains health care’s largest market. It is dominated by drugs for the treatment of hypertension, hyperlipidemia, thrombosis, and cardiomyopathy, as well as devices for coronary and peripheral vascular interventions, rhythm management, and valve repair. The Forum was based around how these traditional fields are being transformed by innovative approaches combining new therapies, ‘omics, digital diagnostics, education and engagement with new delivery platforms to significantly enhance the lives of millions of patients worldwide.

Keynoters

Robert Bradway

CEO, Amgen

Michael Mahoney

CEO, Boston Scientific

George Barrett

CEO, Cardinal Health

Omar Ishrak, PhD

CEO, Medtronic

John Lechleiter, PhD

Chairman, Eli Lilly and Company

John Flannery

CEO, GE Healthcare

Frans van Houten

CEO, Philips

Michael Mussallem

CEO, Edwards Lifesciences

Timothy Ring

CEO, Bard

Tony Coles, MD

CEO, Yumanity Therapeutics

Jessica Mega, MD

CMO, Verily

Nancy Brown

CEO, American Heart Association

Gary Gibbons, MD

Director, NHLBI

Jonathan Rennert

CEO, ZOLL Medical

Michael Minogue

CEO, Abiomed

Stéphane Bancel

CEO, Moderna

Robert Califf, MD

Commissioner (former), Food and Drug Administration

Tamara Syrek Jensen

Director, Coverage and Analysis Group, CMS

Betsy Nabel, MD

President, Brigham and Women's Hospital

Paul Fonteyne

CEO, Boehringer Ingelheim USA

Paul LaViolette

Managing Partner and COO, SV Life Sciences Advisers

Michael Jaff, DO

President, Newton-Wellesley Hospital, Partners HealthCare; Professor of Medicine, Harvard Medical School

Ora Pescovitz, MD

SVP and US Medical Leader, Eli Lilly and Company

Jean-François Formela, MD

Partner, Atlas Venture

Joseph Loscalzo, MD, PhD

Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital; Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School

Katrina Armstrong, MD

Physician-in-Chief, Department of Medicine, Massachusetts General Hospital; Jackson Professor of Clinical Medicine, Harvard Medical School

Jeff Mirviss

SVP and President, Peripheral Interventions, Boston Scientific

Marc Semigran, MD

CMO, MyoKardia

Ludovic Helfgott

Global VP, Cardiovascular, Renal and Metabolism, AstraZeneca

Panels

Day One: Monday, May 1, 2017

First Look: The Next Wave of Cardiology Breakthroughs

Discovery Café Breakout Sessions: Sharing Perspectives

Opening Remarks

  • Anne Klibanski, MD
    Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School
  • David Torchiana, MD
    CEO, Partners HealthCare

Reinventing Cardiac Care

  • Calum MacRae, MD, PhD
    Chief of Cardiovascular Medicine, BWH; Associate Professor of Medicine,Harvard Medical School
  • Anthony Rosenzweig, MD
    Chief, Cardiology Division, MGH; Professor of Medicine, Harvard Medical School

 

CEO Roundtable: Today's Learning, Tomorrow's Opportunities

  • Benjamin Pless
    Executive in Residence, Partners HealthCare Innovation
  • John Flannery
    CEO, GE Healthcare
  • Michael Minogue
    CEO, Abiomed
  • Michael Mussallem
    CEO, Edwards Lifesciences
  • Timothy Ring
    CEO, Bard
  • Lewis Sandy, MD
    EVP, Clinical Advancement, UnitedHealth Group

Tackling the AFib Epidemic

  • Jagmeet Singh, MD, DPhil
    Associate Chief, Cardiology Division, MGH Heart Center; Professor of Medicine, Harvard Medical School
  • Patrick Ellinor, MD, PhD
    Director, Cardiac Arrhythmia Service, MGH; Associate Professor, Harvard Medical School
  • Colleen Fowler
    VP, GM, AF Solutions, Medtronic
  • Parashar Patel
    VP, Global Health Policy, Boston Scientific
  • Michael Rousseau
    President, Cardiovascular and Neuromodulation, Abbott
  • Steven Zelenkofske, DO
    VP US Medical Affairs, CVMD TA, AstraZeneca

1:1 Fireside Chat: Omar Ishrak, PhD, CEO, Medtronic

  • Paul LaViolette
    Managing Partner & COO, SV Life Sciences Advisers
  • Omar Ishrak, PhD
    CEO, Medtronic

Heart Failure's Therapeutic Mandate

  • Akshay Desai, MD
    Director, Heart Failure Disease Management, BWH; Associate Professor, Harvard Medical School
  • Philip Adamson, MD
    VP and Medical Director, Abbott
  • Craig Basson, MD, PhD
    VP, Global Translational Medicine Head (CVM), Novartis Institutes for BioMedical Research; Senior Lecturer, Harvard Medical School
  • Marc Semigran, MD
    CMO, Myokardia
  • Kenneth Stein, MD
    SVP, CMO, Global Health Policy, Rhythm Management, Boston Scientific

CLINICAL HIGHLIGHT: A New Chapter of PAD

  • Michael Jaff, DO
    President, Newton-Wellesley Hospital, Partners HealthCare; Professor of Medicine, Harvard Medical School
  • Douglas Drachman, MD
    Director, Cardiology and Interventional Cardiology Fellowship Programs, MGH; Assistant Professor of Medicine, Harvard Medical School
  • Tamara Syrek Jensen
    Director, Coverage and Analysis Group, CMS
  • Misti Malone, PhD
    Chief, Peripheral Interventional Devices Branch, Food and Drug Administration
  • Shaden Marzouk, MD
    CMO, Cardinal Health
  • Matthew Menard, MD
    Co-Director, Endovascular Surgery, BWH; Assistant Professor, Harvard Medical School
  • Jeff Mirviss
    SVP and President, Peripheral Interventions, Boston Scientific

Day Two: Tuesday, May 2, 2017

FOCUS SESSION: Japan Today: Advancing Cardiometabolic Therapies

  • Masanori Aikawa, MD, PhD
    Yoshiro Miwa Associate Chair and Founding Director, Center for Interdisciplinary Cardiovascular Sciences, BWH
  • Carsten Brunn, PhD
    Head of Pharmaceuticals, Americas Region, Bayer
  • Hiroyuki Kawabata
    Director, Health & Welfare Department, JETRO New York
  • Makoto Suematsu, MD, PhD
    President, Japan Agency for Medical Research and Development
  • Eiji Tanaka, PhD
    President, Head of Global Business Development, Mitsubishi Tanabe Pharma Holdings America, Inc.

Pricing to Enable Affordability and Innovation

  • Peter Slavin, MD
    President, MGH
  • Katrina Armstrong, MD
    Physician-in-Chief, Department of Medicine, MGH; Jackson Professor of Clinical Medicine, Harvard Medical School
  • George Barrett
    CEO, Cardinal Health
  • Paul Fonteyne
    CEO, Boehringer Ingelheim USA
  • Robert Ford
    EVP, Medical Devices, Abbott
  • Benjamin Scirica, MD
    Director of Innovation, Cardiovascular Division, Senior Investigator, TIMI Study Group, BWH; Associate Professor of Medicine, Harvard Medical School

CLINICAL HIGHLIGHT: Emerging Devices for Complex Structural Heart Disease

  • Jason Mills
    Managing Director, Head of US Healthcare Research, Canaccord Genuity
  • Michael Dale
    Divisional Vice President and General Manager, Structural Heart, Abbott
  • Ian Meredith, PhD
    EVP, Global CMO, Boston Scientific
  • Patrick O’Gara, MD
    Director, Clinical Cardiology, Executive Medical Director, BWH; Professor of Medicine, Harvard Medical School
  • Stanton Rowe
    CVP, Advanced Technology, CSO, Edwards Lifesciences
  • Sean Salmon
    SVP and President, Coronary & Structural Heart, Medtronic

1:1 Fireside Chat: John Lechleiter, PhD, Chairman, Eli Lilly

  • Susan Dentzer
    CEO, Network for Excellence in Health Innovation
  • John Lechleiter, PhD
    Chairman, Eli Lilly and Company

Personal Monitoring for Disease Management

  • Joe Kvedar, MD
    VP, Connected Health, Partners HealthCare; Associate Professor of Dermatology, Harvard Medical School
  • Adam Landman, MD
    CIO, VP, BWH; Course Co-Director, Harvard Medical School
  • Michael Reitermann
    COO, Siemens Healthineers
  • Jonathan Rennert
    CEO, Zoll Medical
  • Stanley Shaw, MD, PhD
    CSO, One Brave Idea, BWH; Associate Dean for Executive Education, Harvard Medical School

1:1 Fireside Chat: Robert Bradway, CEO, Amgen

  • Scott Sperling
    Co-President, Thomas H Lee Partners
  • Robert Bradway
    CEO, Amgen

Austen-Braunwald Award

  • Brigham and Women's Hospital Winner:
    Benjamin Olenchock, MD, PhD, Cardiovascular Medicine Specialist, BWH; Instructor in Medicine, Harvard Medical School
  • Massachusetts General Hospital Winner:
    Steven Lubitz, MD, Cardiac Electrophysiologist, MGH; Assistant Professor of Medicine, Harvard Medical School

Global Clinical Trials: Next Generation Design and Scalability

  • Marc Sabatine, MD
    Chairman, TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, BWH
  • Elisabeth Björk, MD, PhD
    VP, Cardiovascular & Metabolic Disease Head, Global Medicines Development, AstraZeneca
  • Daniel Bloomfield, MD
    SVP, Global Clinical Research, Therapeutic Area Head, Cardiometabolic & Womens Health, MRL Lead, China R&D, Merck
  • Jonathan Plehn, MD
    VP Cardiovascular Medicine, Covance
  • Norman Stockbridge, MD, PhD
    Director, Division of Cardiovascular and Renal Products, Food and Drug Administration
  • Scott Wasserman, MD
    VP, Global Development, Amgen

Precision Cardiovascular Medicine: What is Different This Time

  • Alex de Winter, PhD
    Managing Director, GE Ventures
  • Sean Harper, MD
    EVP, R&D, Amgen
  • Kevin Hrusovsky
    CEO, Quanterix
  • Dean Li, MD, PhD
    VP, Head Translational Medicine, Merck
  • David Milan, MD
    Assistant in Medicine, MGH; Assistant Professor, Harvard Medical School
  • Christine Seidman, MD
    Director, Cardiovascular Genetics Center, BWH; Thomas W. Smith Professor

CV Investing in the Next Decade

  • Meg Tirrell
    Reporter, CNBC
  • Leslie Bottorff
    Managing Director, Healthcare, GE Ventures
  • Jean-François Formela, MD
    Partner, Atlas Venture
  • Bob Hopkins
    Managing Director, US Medical Technology, Equity Research, Bank of America Merrill Lynch
  • Roger Kitterman
    VP, Venture, Partners HealthCare
  • James Topper, MD, PhD
    Managing General Partner, Frazier Healthcare Partners

CLINICAL HIGHLIGHT: Optimizing Care for the 51%: New Market Opportunities

  • Cathy Minehan
    Managing Director, Arlington Advisory Partners
  • Nancy Brown
    CEO, American Heart Association
  • Christine Albert, MD
    Center for Arrhythmia Prevention, BWH; Professor of Medicine, Harvard Medical School
  • Adele Gulfo
    EVP & Head, Global Commercial Development, Mylan
  • Allison Kean, MD
    CV Therapeutic Area Lead, Global Business Development, Pfizer
  • Paul Underwood, MD
    Medical Director, Boston Scientific
  • Malissa Wood, MD
    Co-Director, MGH Heart Center Corrigan Women's

Disruptive Therapeutic Platforms: New Tools, New Outcomes

  • Tony Coles, MD
    CEO, Yumanity Therapeutics
  • Stéphane Bancel
    CEO, Moderna
  • Katrine Bosley
    CEO, Editas Medicine
  • Mark Cobbold, MD, PhD
    Center for Cancer Immunology, MGH; Member of the Faculty of Medicine, Harvard Medical School
  • John Maraganore, PhD
    CEO, Alnylam
  • Ryuichi Morishita, MD, PhD
    Founder, AnGes

Wednesday, May 3, 2017

1:1 Fireside Chat: Robert Califf, MD, Commissioner (former), FDA

  • Joseph Loscalzo, MD, PhD
    Chairman, Department of Medicine, Physician-in-Chief, BWH; Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School
  • Robert Califf, MD
    Commissioner (former), Food and Drug Administration

Innovation in Translational Trials

  • Mason Freeman, MD
    Director, Translational Research Center, MGH; Professor of Medicine, Harvard Medical School
  • Seigo Izumo, MD
    SVP, Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan, Takeda
  • John Lepore, MD
    SVP, R&D Pipeline, GlaxoSmithKline
  • Jessica Mega, MD
    CMO, Verily
  • Alan Moses, MD
    SVP, Global CMO, Novo Nordisk
  • Sy Pretorius, MD
    SVP & CSO, PAREXEL International

1:1 Fireside Chat: Michael Mahoney, CEO, Boston Scientific

  • Edward Lawrence
    Chairman, Board of Directors, Partners HealthCare; Retired Partner, Ropes & Gray
  • Meg Tirrell
    Reporter, CNBC
  • Michael Mahoney
    CEO, Boston Scientific

New Targets in Coronary Artery Disease

  • Sekar Kathiresan, MD
    Director, Center for Human Genetic Research, MGH; Associate Professor of Medicine, Harvard Medical School
  • Aarif Khakoo, MD
    VP Research, Cardiometabolic Disorders Therapeutic Area Head, Site Head Amgen San Francisco, Amgen
  • Clive Meanwell, MD, PhD
    CEO, The Medicines Company
  • Paul Ridker, MD
    Director, Center for Cardiovascular Disease Prevention, BWH; Eugene Braunwald Professor of Medicine, Harvard Medical School
  • Craig Sponseller, MD
    CMO, Kowa Pharmaceuticals

1:1 Fireside Chat: Gary Gibbons, MD, NHLBI

  • Elizabeth Nabel, MD
    President, Brigham Health; Professor of Medicine, Harvard Medical School
  • Gary Gibbons, MD
    Director, NHLBI

The Skinny on Fat: Therapeutic Opportunities

  • Ora Pescovitz, MD
    SVP and US Medical Leader, Eli Lilly and Company
  • Morris Birnbaum, MD, PhD
    SVP and CSO, CVMET, Pfizer
  • Ludovic Helfgott
    Global VP, Cardiovascular, Renal and Metabolism, AstraZeneca
  • Thomas Hughes, PhD
    CEO, Zafgen
  • Lee Kaplan, MD, PhD
    Director, Obesity, Metabolism & Nutrition Institute, MGH; Associate Professor, Harvard Medical School
  • Bruce Spiegelman, PhD
    Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Disruptive Dozen: 12 Technologies That Will Reinvent Cardiovascular Care

  • Calum MacRae, MD, PhD
    Chief of Cardiovascular Medicine, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School
  • Anthony Rosenzweig, MD
    Chief, Cardiology Division, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Sponsors

Boston Scientific logo
Amgen logo
Lilly
GE Medical logo
Novartis logo
Pfizer
astrazeneca
Bayer - Footer
Bard Logo
Edwards footer
Medtronic
mintzlogo
Novo Nordisk
STAT